WO2018158249A1 - Composition pharmaceutique stable à température ambiante comprenant de l'acide carglumique - Google Patents

Composition pharmaceutique stable à température ambiante comprenant de l'acide carglumique Download PDF

Info

Publication number
WO2018158249A1
WO2018158249A1 PCT/EP2018/054808 EP2018054808W WO2018158249A1 WO 2018158249 A1 WO2018158249 A1 WO 2018158249A1 EP 2018054808 W EP2018054808 W EP 2018054808W WO 2018158249 A1 WO2018158249 A1 WO 2018158249A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
room temperature
temperature stable
solid pharmaceutical
composition according
Prior art date
Application number
PCT/EP2018/054808
Other languages
English (en)
Inventor
Salvatore AGOSTINO GIAMMILLARI
Giuseppe Maccari
Original Assignee
Dipharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dipharma S.A. filed Critical Dipharma S.A.
Publication of WO2018158249A1 publication Critical patent/WO2018158249A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La présente invention concerne des formes posologiques de médicament stables à température ambiante élevée comprenant un activateur de Carbamoyl Phosphate synthétase 1 (CPS 1) sensible à la dégradation, notamment induite par l'humidité; et au moins un excipient pharmaceutiquement acceptable.
PCT/EP2018/054808 2017-02-28 2018-02-27 Composition pharmaceutique stable à température ambiante comprenant de l'acide carglumique WO2018158249A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17000307 2017-02-28
EP17000307.3 2017-02-28

Publications (1)

Publication Number Publication Date
WO2018158249A1 true WO2018158249A1 (fr) 2018-09-07

Family

ID=58277137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/054808 WO2018158249A1 (fr) 2017-02-28 2018-02-27 Composition pharmaceutique stable à température ambiante comprenant de l'acide carglumique

Country Status (1)

Country Link
WO (1) WO2018158249A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020239882A1 (fr) * 2019-05-30 2020-12-03 Recordati Industria Chimica E Farmaceutica S.P.A. Formulation pharmaceutique pour l'acide carglumique
WO2021203703A1 (fr) * 2020-04-07 2021-10-14 中国科学院深圳先进技术研究院 Utilisation d'acide carglumique dans la préparation de médicaments pour la prévention et le traitement de coronavirus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2777696A1 (fr) 2013-03-15 2014-09-17 Navinta, llc. Préparation de formes posologiques pharmaceutiques stables
CN105056246A (zh) * 2015-08-18 2015-11-18 武汉武药科技有限公司 一种卡谷氨酸固体组合物及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2777696A1 (fr) 2013-03-15 2014-09-17 Navinta, llc. Préparation de formes posologiques pharmaceutiques stables
CN105056246A (zh) * 2015-08-18 2015-11-18 武汉武药科技有限公司 一种卡谷氨酸固体组合物及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. MADDILETI ET AL: "Polymorphism in anti-hyperammonemic agent N-carbamoyl-L-glutamic acid", CRYSTENGCOMM, vol. 17, no. 28, 1 January 2015 (2015-01-01), pages 5252 - 5265, XP055474622, DOI: 10.1039/C5CE00116A *
VALAYANNOPOULOS V. ET AL., ORPHANET JOURNAL OF RARE DISEASES, vol. 11, 2016, pages 32

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020239882A1 (fr) * 2019-05-30 2020-12-03 Recordati Industria Chimica E Farmaceutica S.P.A. Formulation pharmaceutique pour l'acide carglumique
WO2021203703A1 (fr) * 2020-04-07 2021-10-14 中国科学院深圳先进技术研究院 Utilisation d'acide carglumique dans la préparation de médicaments pour la prévention et le traitement de coronavirus

Similar Documents

Publication Publication Date Title
CN102946869B (zh) γ-羟基丁酸的速释制剂及剂型
US20080008752A1 (en) Pharmaceutical compositions of memantine
CN102341098A (zh) 具有高负荷的加巴喷丁前药的口服剂型
US11883399B2 (en) Bromocriptine formulations
CZ227595A3 (en) Pharmaceutical preparation and oral dosing forms
US10668073B2 (en) Pharmaceutical composition containing 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof
WO2018158249A1 (fr) Composition pharmaceutique stable à température ambiante comprenant de l'acide carglumique
AU2012288632B2 (en) New (trimethoxyphenylamino)pyrimidinyl formulations
WO2014163314A1 (fr) Composition pharmaceutique capable de contrôler facilement un modèle de dissolution de lacosamide ou de sel pharmaceutiquement acceptable de celui-ci
RU2613192C1 (ru) Таблетки клозапина с пролонгированным высвобождением
CN107334744B (zh) 盐酸美金刚药物组合物和制法
US20100087538A1 (en) Drug substance preparations, pharmaceutical compositions and dosage forms
KR101583452B1 (ko) 위장질환 치료용 의약 조성물
JP6328138B2 (ja) Ｎ−［５−［２−（３，５−ジメトキシフェニル）エチル］−２ｈ−ピラゾール−３−イル］−４−［（３ｒ，５ｓ）−３，５−ジメチルピペラジン−１−イル］ベンズアミドの医薬製剤
EP2801350B1 (fr) Formulations pharmaceutiques de lacosamide
NO329809B1 (no) Perorale sammensetninger av levosimendan med kontrollert frigjoring
US10085991B2 (en) Formulation inhibiting effects of low acid environment
CN112516097B (zh) 一种苯磺酸左旋氨氯地平组合物
EP4205730A1 (fr) Composition pharmaceutique à forme galénique à dose unique pour le traitement ou la prévention de l'hypertension et de l'hyperlipidémie
TW202220642A (zh) 三苯基鈣敏感性化合物之調配物
RU2266745C2 (ru) Противогрибковая фармацевтическая композиция
MX2013005687A (es) Formas de dosificación sólida de oleil fosfocolina.
US20120263791A1 (en) Fomulation comprising 1 h-quinazoline-2, 4-dione ampa receptor antagonists, in the form of immediate release tablets and preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18709499

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18709499

Country of ref document: EP

Kind code of ref document: A1